Evaluation of antibody-dependent cell cytotoxicity using lactate dehydrogenase (LDH) measurement

Methods in Molecular Biology

Volumn 988, Issue , 2013, Pages 305-317

  Broussas, Matthieu ^a   Broyer, Lucile ^a   Goetsch, Liliane ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

ADCC; Antibody dependent cell cytotoxicity; Herceptin; LDH release; Non colorimetric method

Indexed keywords

CHROMIUM 51; IMMUNOGLOBULIN G1 ANTIBODY; LACTATE DEHYDROGENASE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; ENZYME RELEASE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; IN VITRO STUDY; INCUBATION TIME; NATURAL KILLER CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PURIFICATION; TARGET CELL; TUMOR CELL; ANIMAL; CELL SEPARATION; CHEMISTRY; DRUG SCREENING; ENZYME ASSAY; ENZYMOLOGY; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; METHODOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SEPARATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ASSAYS; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; L-LACTATE DEHYDROGENASE;

EID: 84883033242     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-327-5_19     Document Type: Article

References (23)

1. Glennie MJ, French RR, Cragg MS, Taylor RP (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44: 3823-3837
2. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 8: 140-174
3. Oflazoglu E, Audoly LP (2010) Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2: 14-19
4. Galizia G, Lieto E, De Vita F, Orditura M, Castellano P, Troiani T et al (2007) Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 26: 3654-3660
5. Pescovitz MD (2006) Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 6: 859-866
6. Ravandi F, O'Brien S (2005) Alemtuzumab. Expert Rev Anticancer Ther 5: 39-51
7. Watanabe M, Wallace PK, Keler T, Deo YM, Akewanlop C, Hayes DF (1999) Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Breast Cancer Res Treat 53: 199-207
8. Correia IR (2010) Stability of IgG isotypes in serum. MAbs 2: 221-232
9. Yoo EM, Yu LJ, Wims LA, Goldberg D, Morrison SL (2010) Differences in N-glycan structures found on recombinant IgA1 and IgA2 produced in murine myeloma and CHO cell lines. MAbs 2: 320-334
10. Liu XY, Pop LM, Vitetta ES (2008) Engineering therapeutic monoclonal antibodies. Immunol Rev 222: 9-27
11. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19: 275-290
12. Bryceson YT, March ME, Ljunggren HG, Long EO (2006) Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 214: 73-91
13. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34-47
14. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99: 754-758
15. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S et al (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725
16. Jefferis R (2009) Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 30: 356-362
17. Bryceson YT, Chiang SC, Darmanin S, Fauriat C, Schlums H, Theorell J et al (2011) Molecular mechanisms of natural killer cell activation. J Innate Immun 3: 216-226
18. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21: 3940-3947
19. Beck A, Wurch T, Bailly C, Corvaia N (2010) Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10: 345-352
20. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L et al (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103: 4005-4010
21. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S et al (2004) Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa.J Mol Biol 336: 1239-1249
22. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG et al (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277: 26733-26740
23. Beum PV, Lindorfer MA, Taylor RP (2008) Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol 181: 2916-2924